Aptorum Group Ltd Class A
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.2
- Today's High:
- $2.7
- Open Price:
- $2.27
- 52W Low:
- $2.79
- 52W High:
- $17.8
- Prev. Close:
- $2.27
- Volume:
- 40738
Company Statistics
- Market Cap.:
- $11.00 million
- Book Value:
- 6.343
- Revenue TTM:
- $1.43 million
- Operating Margin TTM:
- -1268.94%
- Gross Profit TTM:
- $81854
- Profit Margin:
- 0%
- Return on Assets TTM:
- -40.74%
- Return on Equity TTM:
- -60.5%
Company Profile
Aptorum Group Ltd Class A had its IPO on 2018-12-18 under the ticker symbol APM.
The company operates in the Healthcare sector and Biotechnology industry. Aptorum Group Ltd Class A has a staff strength of 26 employees.
Stock update
Shares of Aptorum Group Ltd Class A opened at $2.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.2 - $2.7, and closed at $2.68.
This is a +18.06% increase from the previous day's closing price.
A total volume of 40,738 shares were traded at the close of the day’s session.
In the last one week, shares of Aptorum Group Ltd Class A have increased by +19.64%.
Aptorum Group Ltd Class A's Key Ratios
Aptorum Group Ltd Class A has a market cap of $11.00 million, indicating a price to book ratio of 0.8041 and a price to sales ratio of 12.4724.
In the last 12-months Aptorum Group Ltd Class A’s revenue was $1.43 million with a gross profit of $81854 and an EBITDA of $-16987172. The EBITDA ratio measures Aptorum Group Ltd Class A's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aptorum Group Ltd Class A’s operating margin was -1268.94% while its return on assets stood at -40.74% with a return of equity of -60.5%.
In Q2, Aptorum Group Ltd Class A’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.3%.
Aptorum Group Ltd Class A’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aptorum Group Ltd Class A’s profitability.
Aptorum Group Ltd Class A stock is trading at a EV to sales ratio of 12.237 and a EV to EBITDA ratio of -0.7063. Its price to sales ratio in the trailing 12-months stood at 12.4724.
Aptorum Group Ltd Class A stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $24.02 million
- Total Liabilities
- $8.21 million
- Operating Cash Flow
- $1.36 million
- Capital Expenditure
- $75277
- Dividend Payout Ratio
- 0%
Aptorum Group Ltd Class A ended 2024 with $24.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $24.02 million while shareholder equity stood at $22.65 million.
Aptorum Group Ltd Class A ended 2024 with $0 in deferred long-term liabilities, $8.21 million in other current liabilities, 35703257.00 in common stock, $-57422767.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.07 million and cash and short-term investments were $4.22 million. The company’s total short-term debt was $3,361,755 while long-term debt stood at $0.
Aptorum Group Ltd Class A’s total current assets stands at $9.32 million while long-term investments were $9.74 million and short-term investments were $153905.00. Its net receivables were $973428.00 compared to accounts payable of $75207.00 and inventory worth $29704.00.
In 2024, Aptorum Group Ltd Class A's operating cash flow was $1.36 million while its capital expenditure stood at $75277.
Comparatively, Aptorum Group Ltd Class A paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.68
- 52-Week High
- $17.8
- 52-Week Low
- $2.79
- Analyst Target Price
- $115
Aptorum Group Ltd Class A stock is currently trading at $2.68 per share. It touched a 52-week high of $17.8 and a 52-week low of $17.8. Analysts tracking the stock have a 12-month average target price of $115.
Its 50-day moving average was $2.16 and 200-day moving average was $3.42 The short ratio stood at 0.72 indicating a short percent outstanding of 0%.
Around 3163.1% of the company’s stock are held by insiders while 404.6% are held by institutions.
Frequently Asked Questions About Aptorum Group Ltd Class A
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.